News
Public · Published
Longeveron Announces Updated Results from ELPIS II Phase 2b Clinical Trial Evaluating Laromestrocel as a Potential Treatment for Hypoplastic Left Heart Syndrome (HLHS)
Longeveron reported updated phase 2b ELPIS II trial results for laromestrocel in children with hypoplastic left heart syndrome, a congenital heart defect. The primary endpoint of right ventricular ejection fraction increase at month 12 was not met, but the secondary endpoint of major adverse cardiac events reached statistical significance: 8 events in the standard of care arm versus 1 in the treatment arm (P=0.043).
Published:
Updated:
What happened
Longeveron reported updated phase 2b ELPIS II trial results for laromestrocel in children with hypoplastic left heart syndrome, a congenital heart defect. The primary endpoint of right ventricular ejection fraction increase at month 12 was not met, but the secondary endpoint of major adverse cardiac events reached statistical significance: 8 events in the standard of care arm versus 1 in the treatment arm (P=0.043).
Confirmed
Global impact / market context
A statistically significant drop in major adverse cardiac events, from 8 to 1, could support laromestrocel's clinical value even though the primary heart-function endpoint failed. If confirmed in larger studies, fewer cardiac events could reduce hospital stays and treatment costs for these children, strengthening Longeveron's case for further funding and regulatory discussions.
Analyst inference
Longeveron is a clinical-stage biotechnology company with no approved product, so investors weigh trial readouts heavily. Mixed results, a missed primary endpoint but a positive secondary endpoint, leave the stock's direction dependent on how much credibility the event data carries with regulators, partners, and future financing sources such as new investors or collaborators.
Analyst inference
What to watch
- Longeveron says the ELPIS II data in hypoplastic left heart syndrome were selected for a late-breaking science podium presentation at the American Heart Association's 2026 Scientific Sessions. Confirmed
- The company plans to continue analyzing additional ELPIS II data, so investors should watch for further secondary endpoint results and any company statements on next-step trial design or regulatory talks. Proposed
- Watch Longeveron's cash position and spending plans, because a clinical-stage company without approved products may need new funding to advance laromestrocel after mixed trial results. Analyst inference